v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities:      
Net loss $ (76,240) $ (33,592) $ (21,279)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation 5,518 5,402 3,113
Amortization expense - right-of-use assets - operating and finance leases 4,405 4,849 2,834
Stock-based compensation 9,971 14,531 11,593
Provision (recovery) for credit losses (65) 4 342
Equity securities earned from research and development activities ($0, ($1,245), and ($1,955) from a related party) (213) (1,245) (1,955)
Unrealized gain on non-marketable securities ($0, ($208), and ($983) from a related party) 0 (208) (1,272)
Asset impairment and other charges 9,984 0 0
Impairment of investment in non-marketable securities 12,215 0 0
Other non-cash items 4 (29) (19)
Changes in operating assets and liabilities:      
Financial assets 20,247 (3,225) (9,156)
Inventories (656) (869) (196)
Prepaid expenses and other assets (865) 181 (2,268)
Accounts payable 2,287 207 268
Accrued compensation and other accrued liabilities (14,041) 5,983 6,575
Other long-term liabilities (5,341) (5,223) (4,147)
Deferred revenue ($0, $0, $245 to a related party) (19,848) 24,518 1,300
Net cash provided by (used in) operating activities (52,638) 11,284 (14,267)
Investing activities:      
Purchase of property and equipment (4,418) (8,307) (13,828)
Proceeds from sale of property and equipment 751 29 36
Investment in non-marketable securities ($0, $0, and ($7,630) in a related party) (1,191) (5,300) (7,630)
Net cash used in investing activities (4,858) (13,578) (21,422)
Financing activities:      
Proceeds from exercises of stock options 422 955 5,180
Proceeds from issuance of common stock in connection with public offering 8,652 0 0
Costs incurred in connection with issuance of common stock at public offering (503) (42) (207)
Taxes paid related to net share settlement of equity awards (404) (1,488) (1,206)
Net cash provided by (used in) financing activities 8,167 (575) 3,767
Net decrease in cash, cash equivalents and restricted cash (49,329) (2,869) (31,922)
Cash, cash equivalents and restricted cash at the beginning of the year 116,026 118,895 150,817
Cash, cash equivalents and restricted cash at the end of the year 66,697 116,026 118,895
Supplemental disclosure of cash flow information:      
Interest paid 44 34 14
Income taxes 194 100 102
Supplemental non-cash investing and financing activities:      
Capital expenditures incurred but not yet paid 1,068 897 2,533
Cash and cash equivalents 65,116 113,984 116,797
Restricted cash, current and non-current 1,581 2,042 2,098
Total cash, cash equivalents and restricted cash at the end of the period $ 66,697 $ 116,026 $ 118,895

Source

PDF HTML 10-K Filing
ZIP XBRL